Other biologics approved for severe T2 asthma targeting anti-IL-5 mab (mepolizumab, benralizumab, reslizumab for eosinophilic asthma) or the anti-IgE ab omalizumab have not shown sufficient efficacy in AD for approval [3]. The gene discussed is IGHE; the disease is Alzheimer disease.